1Chang J,Clark GM,Allred DC,et al.Survival of patients with metastatic breast carcinoma:importance of prognostic markers of the primary tumor[J].Cancer,2003,97(3):545～53.
2Volpi A,Nanni O,Dwpaola F,et al.HER-2 expression and cell proliferation:prognostic markers in patients with node-negative breast cancer[J].J Clin Oncol,2003,21(14):2708～12.
3Bilous M,Ades C,Armes J,et al.Predicting the HER-2 status of breast cancer from basic histopathology data:an analysis of 1500breast cancers as part of the HER2000 International Study[J].Breast,2003,12(2):92～8.
4Barnes NL,Khavari S,Boland GP,et al.Absence of HER-4 expression predicts recurrence of ductual carcinoma in situ of the breast[J].Clin Cancer Res,2005,11(6):2163～8.
6Bull SB,Ozcelik H,Pinnaduwage D,et al.The combination of P53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer[J].J Clin Oncol,2004,22(1):86～96.
7Linjawi A,Kontogiannea M,Halwani F,et al.Prognostic significance of P53,bcl-2 and Bax expression in early breast cancer[J].J Am Coll Surg,2004,198(1):83～90.
8Yamashita H,Nishio M,Toyama T,et al.Coexistence of HER-2over-expression and P53 protein accumulation is a strong prognostic molecular marker in breast cancer[J].Breast Cancer Res,2004,6(1):R24～30.
9Sirvent JJ,Aguilar MC,Olona M,et al.Prognostic value of apoptosis in breast cancer (pT1～pT2); A TUNEL P53,bcl-2,bag-1and Bax immunohistochemical study[J].Histol Histopathol,2004,19(3):759～70.
10Cardoso F,Paesmans M,Larsimont D,et al.Potential predictive value of bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer[J].Clin Breast Cancer,2004,5(5):364～9.
